India’s Controller General has approved generic versions of Gilead Sciences’ (NASDAQ:GILD) remdesivir for the treatment of COVID-19.
Two domestic drugmakers, Hyderabad-based Hetero
and Mumbai-based Cipla, plan to launch their offerings within a week at
Rs 5,000 – 6,000 ($65 – 78) and Rs 3,000 – 4,000 ($39 – 52),
respectively.
According to current Indian government guidelines,
a COVID-19 patient may need five-to-six doses, implying a total
treatment cost of the antiviral as low as $195.
Gilead has yet to announce the price in the U.S.
but it’s safe to say it will be substantially higher. Drug cost watchdog
ICER issued a report last month that the medicine would be cost-effective at $4,500 per course of treatment.
https://seekingalpha.com/news/3584771-remdesivir-okd-in-india-39-52-per-dose
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.